How does AVXT's PB Ratio compare to its peers?

Insufficient data to calculate AVXT's Price-To-Book Ratio vs. peers for valuation analysis.

How does AVXT's PB Ratio compare vs other companies in the US Biotechs Industry?

Insufficient data to calculate AVXT's Price-To-Book Ratio vs. industry for valuation analysis.

What is AVXT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AVXT's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of AVXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate AVXT's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

AVAX Technologies (OTCPK:AVXT) - Stock Price, News & Analysis

AVXT Stock Overview

A development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. More details

AVXT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Does not have a meaningful market cap ($7K)

My Notes

Capture your thoughts, links and company narrative

AVAX Technologies, Inc. Competitors

Molecular Templates

OTCPK:MTEM

US$2.0k

Vaxxinity

OTCPK:VAXX

US$12.7k

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Innovation Pharmaceuticals

OTCPK:IPIX

US$52.9k

Price History & Performance

Summary of share price highs, lows and changes for AVAX Technologies
Historical stock prices
Current Share Price	US$0.00001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-90.00%
5 Year Change	-99.29%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	AVXT	US Biotechs	US Market
7D	0%	-4.2%	0.2%
1Y	n/a	-3.0%	23.1%

Return vs Industry: Insufficient data to determine how AVXT performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how AVXT performed against the US Market.

Price Volatility

Is AVXT's price volatile compared to industry and market?
AVXT volatility
AVXT Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.4%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.3%
10% least volatile stocks in US Market	3.0%

Stable Share Price: AVXT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AVXT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1990	n/a	n/a	www.avax-tech.com

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer.

AVAX Technologies, Inc. Fundamentals Summary

How do AVAX Technologies's earnings and revenue compare to its market cap?
AVXT fundamental statistics
Market cap	US$6.89k
Earnings (TTM)	-US$11.99m
Revenue (TTM)	US$142.50k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is AVXT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVXT income statement (TTM)
Revenue	US$142.50k
Cost of Revenue	US$0
Gross Profit	US$142.50k
Other Expenses	US$12.14m
Earnings	-US$11.99m

Last Reported Earnings

Dec 31, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did AVXT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 00:51
End of Day Share Price	2024/12/30 00:00
Earnings	2010/12/31
Annual Earnings	2010/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AVAX Technologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.